[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342745-105":3,"doc-detail-342745-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","oncolytic-adenovirus-for-the-targeting-of-paclitaxel-resistant-breast-cancer-stem-cells-abstract","Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells - Abstract","","Adjuvant systemic therapies reduce the risk of breast cancer recurrence and metastasis, yet resistance can arise through breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) is a promising approach because it can selectively target cancer, but its ability to target BCSCs was unclear. A Cox-2 promoter-controlled Ad5/3 fiber-modified OAd encoding hNIS was tested in breast cancer models using BCSC-enriched ER+ paclitaxel-resistant cells and tumorsphere assays. OAd-hNIS increased binding and oncolysis in ER+ cells while showing no activity in normal mammary epithelial cells, improved NIS expression via adenovirus death protein deletion, inhibited tumorsphere formation after early infection, and reversed paclitaxel resistance. It also destroyed established tumorspheres after seven days, supporting its potential for studying and targeting ER+ recurrence and metastasis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/oncolytic-adenovirus-for-the-targeting-of-paclitaxel-resistant-breast-cancer-stem-cells-abstract/342745/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/oncolytic-adenovirus-for-the-targeting-of-paclitaxel-resistant-breast-cancer-stem-cells-abstract/342745.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic strategy tested in the study?","Question",{"text":63,"@type":64},"The study evaluates a Cox-2 promoter-controlled, Ad5/3 fiber-modified oncolytic adenovirus engineered to encode the human sodium iodide symporter (hNIS) for targeting paclitaxel-resistant breast cancer stem cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did OAd-hNIS perform compared with parental cells in targeting BCSCs?",{"text":68,"@type":64},"OAd-hNIS showed superior killing and hNIS expression in targeting TaxR BCSCs, compared with the parental cells.",{"name":70,"@type":61,"acceptedAnswer":71},"Did the treatment affect tumorspheres after they were already formed?",{"text":72,"@type":64},"Yes. OAd-hNIS destroyed already formed tumorspheres seven days after their initiation and inhibited tumorsphere formation when infection occurred early.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342745,1790235934,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",8,"viruses   \nArticle  \nOncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells  \nSacha Robert 1, *, Natasha Ivelisse Roman Ortiz 2, Christopher J. LaRocca 1,3, Julie Hanson Ostrander 3,4 and Julia Davydova 1,3,5, *  \nCitation: Robert, S.; Roman Ortiz, N.I.; LaRocca, C.J.; Ostrander, J.H.; Davydova, J. Oncolytic Adenovirus for the Targeting of PaclitaxelResistant Breast Cancer Stem Cells. Viruses 2024, 16, 567. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/v16040567](10.3390/v16040567)  \nAcademic Editors: Dragomira Majhen, Alan Parker and David T. Curiel  \nReceived: 21 March 2024  \nRevised: 1 April 2024  \nAccepted: 3 April 2024  \nPublished: 5 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA; [clarocca@umn.edu](clarocca@umn.edu)  \n2 Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA; [roman449@umn.edu](roman449@umn.edu)  \n3 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; [hans1354@umn.edu](hans1354@umn.edu)  \n4 Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA  \n5 Institute of Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA  \n* Correspondence: [srobert@umn.edu](srobert@umn.edu) (S.R.); [davyd003@umn.edu](davyd003@umn.edu) (J.D.)  \nAbstract: Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs) . Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically target cancer cells. However, its potential to target BCSCs remains unclear. Here, we evaluated a Cox-2 promoter-controlled, Ad5/3 fiber-modified OAd designed to encode the human sodium iodide symporter (hNIS) in breast cancer models. To confirm the potential of OAds to target BCSCs, we employed BCSC-enriched estrogen receptor-positive (ER+) paclitaxel-resistant (TaxR) cells and tumorsphere assays. OAd-hNIS demonstrated significantly enhanced binding and superior oncolysisin breast cancer cells, including ER+ cells, while exhibiting no activity in normal mammary epithelial cells. We observed improved NIS expression as the result of adenovirus death protein deletion. OAdhNIS demonstrated efficacy in targeting TaxR BCSCs, exhibiting superior killing and hNIS expression compared to the parental cells. Our vector was capable of inhibiting tumorsphere formation upon early infection and reversing paclitaxel resistance in TaxR cells. Importantly, OAd-hNIS also destroyed already formed tumorspheres seven days after their initiation. Overall, our findings highlight the promise of OAd-hNIS as a potential tool for studying and targeting ER+ breast cancer recurrence and metastasis.  \nKeywords: human adenovirus; breast cancer; breast cancer stem cell; chemoresistance; oncolytic vectors; sodium iodide symporter  \n1. Introduction  \nBreast cancer is today the most common cancer diagnosed in women worldwide, replacing lung cancer, with an average risk of 13% for a woman in the United States to develop breast cancer sometime in her life [1] . The most aggressive form of breast cancer types are known as triple-negative, which lack expression of hormone receptors, including estrogen receptor (ER) and/or progesterone receptor (PR) as well as the expression of the human epidermal growth factor receptor 2 (HER2) . Other breast cancer types involve the overexpression of HER2 (HER2+) . However, those breast cancer types represent onl","cbCaieggNHGknLHJ","https://ap.wps.com/l/cbCaieggNHGknLHJ","pdf",7996215,24,"English","# Abstract\n## Introduction","[{\"question\":\"What is the main therapeutic strategy tested in the study?\",\"answer\":\"The study evaluates a Cox-2 promoter-controlled, Ad5/3 fiber-modified oncolytic adenovirus engineered to encode the human sodium iodide symporter (hNIS) for targeting paclitaxel-resistant breast cancer stem cells.\"},{\"question\":\"How did OAd-hNIS perform compared with parental cells in targeting BCSCs?\",\"answer\":\"OAd-hNIS showed superior killing and hNIS expression in targeting TaxR BCSCs, compared with the parental cells.\"},{\"question\":\"Did the treatment affect tumorspheres after they were already formed?\",\"answer\":\"Yes. OAd-hNIS destroyed already formed tumorspheres seven days after their initiation and inhibited tumorsphere formation when infection occurred early.\"}]","Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells - Abstract | PDF",1790047985,60,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c262fa6534b61490a6ce9cffecefa116.webp",983,1390,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f752ef9eafb357ee0490ba56d2c62994.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ca670ec1a55e15c0489f91182a256ec.webp",981,1387,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b64b811d12ac08cb646edd2391034a35.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,133,138,143,146,151,154,158],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":98,"slug":132},"Comic","comic",{"id":134,"doc_module":4,"doc_module_name":25,"category_name":135,"show_sort_weight":136,"slug":137},6,"Technology",50,"technology",{"id":139,"doc_module":4,"doc_module_name":25,"category_name":140,"show_sort_weight":141,"slug":142},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":144,"slug":145},30,"research-report",{"id":147,"doc_module":4,"doc_module_name":25,"category_name":148,"show_sort_weight":149,"slug":150},9,"Religion & Spirituality",20,"religion-spirituality",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":152,"show_sort_weight":149,"slug":153},"World Cup","world-cup",{"id":155,"doc_module":4,"doc_module_name":25,"category_name":156,"show_sort_weight":155,"slug":157},10,"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":55,"slug":161},19,"General","general"]